NCT01063478View on ClinicalTrials.gov

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

January 31, 2012

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

RAD001 (in addition to standard radiation and chemotherapy)

Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001

Trial Locations (1)

60637

University of Chicago Medical Center, Chicago

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Chicago

OTHER